Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Nasal mucosal vaccine composition
US10071155B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10071155-B2 |
| Application number | US-201414916721-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 2, 2014 |
| Priority date | Oct 3, 2013 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method comprising: administering a nasal mucosal vaccine composition to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition comprising: at least one antigen derived from a pathogen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas , and Xanthomonas , or a salt of the lipopolysaccharide. 2. The method according to claim 1 , wherein a mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500. 3. The method according to claim 1 , wherein the method induces humoral immunity. 4. The method according to claim 2 , wherein the method induces humoral immunity. 5. The method according to claim 1 , wherein the lipopolysaccharide is derived from Pantoea agglomerans. 6. The method according to claim 1 , wherein the mucosal vaccine composition is a spray, semi-solid medicine, or solid preparation.
Assignees
Inventors
Classifications
intranasal · CPC title
Streptococcus · CPC title
- A61K39/39Primary
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title
Immunostimulants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10071155B2 cover?
- The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal muc…
- Who is the assignee on this patent?
- Nitto Denko Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).